Aleksey Yefremov

John Ezekiel Roberts

Kevin McCarthy

Michael Sison

Patrick Cunningham

Arun Viswanathan

Frank Mitsch

Hassan Ahmed

Joshua Spector

Matthew Blair

Michael Leithead

Peter Osterland

Bhavesh Lodaya

David Begleiter

Duffy Fischer

Jeffrey Zekauskas

Turner Hinrichs

Vincent Andrews

Adam Hamilton

Aziza Gazieva

John McNulty

Josh Spector

Matthew Deyoe

Salvator Tiano

- Westlake reported **Net Sales of $2.8 billion** and **EBITDA of $313 million** for Q3 2025.  **[0001262823_2216667:0]** **[0001262823_2216667:1]** 
- The company recorded a **net loss of ($782) million**, or **($6.06) per diluted share**, primarily driven by a **$727 million non-cash goodwill impairment charge** in the North America Chlorovinyls business.  **[0001262823_2216667:0]** **[0001262823_2216667:1]** **[0001262823_2216667:6]**  Excluding identified items, diluted EPS was **($0.29)**.  **[0001262823_2216667:8]** 
- The Housing and Infrastructure Products (HIP) segment reported **$1,091 million in sales** and **$215 million in EBITDA**.  **[0001262823_2216667:2]**  Due to slower residential construction, 2025 revenue and EBITDA margin for HIP are now expected at the low end of previously communicated ranges of $4.2-$4.4 billion in sales with a 20%-22% EBITDA margin.  **[0001262823_2216667:2]** 
- The Performance and Essential Materials (PEM) segment saw **$1,747 million in sales** and **$90 million in EBITDA**, with QoQ EBITDA improving due to a **$36 million tailwind from better plant reliability**.  **[0001262823_2216667:4]** 
- Westlake is progressing towards **$200 million of identified company-wide cost savings in 2026**, with the majority in the PEM segment, and anticipates a **~$100 million benefit in 2026 from the Pernis shutdown**.  **[0001262823_2216667:0]** **[0001262823_2216667:5]**  The company has already achieved **~$115 million in cost savings year-to-date**, including **$40 million in Q3 2025**.  **[0001262823_2216667:1]**

Westlake Reports Q3 2025 Results with Net Loss Driven by Goodwill Impairment

- Westlake Corporation reported **Q3 2025 net sales of $2.8 billion and EBITDA of $313 million**.  **[0001262823_2216832_1]** 
- The company recorded a **non-cash impairment charge of $727 million** for the goodwill associated with its North American chlorovinyls business unit and **$17 million** in accrued expenses for facility closures, totaling **$744 million** in identified items.  **[0001262823_2216832_0]** **[0001262823_2216832_1]** 
- The Housing and Infrastructure Products (HIP) segment demonstrated resilience with a **0.5% increase in sales volumes** year-over-year, while the Performance and Essential Materials (PEM) segment faced challenges from softer global demand, resulting in **$1.7 billion in sales** and **$90 million in EBITDA** for Q3 2025.  **[0001262823_2216832_1]** **[0001262823_2216832_4]** 
- Westlake is pursuing significant cost reductions, targeting **$100 million to $175 million** in structural cost savings in 2025 and an additional **$200 million** in 2026, with the Pernis facility closure projected to yield over **$100 million** in annual savings starting next year.  **[0001262823_2216832_1]** **[0001262823_2216832_6]** **[0001262823_2216832_15]**

Westlake Corporation Reports Q3 2025 Results and Significant Impairment Charge

- Westlake Corporation reported **net sales of $2.838 billion** and a **net loss attributable to Westlake Corporation of ($782) million**, or **($6.06) per diluted share**, for the third quarter of 2025.  **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:0]** 
- The Q3 2025 results were significantly impacted by **$744 million** in Identified Items, primarily a **$727 million non-cash impairment charge** related to the goodwill of the North American Chlorovinyls business.  **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:0]** **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:1]** 
- Excluding Identified Items, the company reported a **net loss of ($38) million**, or **($0.29) per diluted share**, and **EBITDA of $313 million** for Q3 2025.  **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:0]** 
- EBITDA excluding Identified Items of **$313 million** decreased sequentially by **$27 million** from Q2 2025 and was lower than **$580 million** in Q3 2024, primarily due to lower average sales prices in the Performance and Essential Materials (PEM) segment and lower sales volume in the Housing and Infrastructure Products (HIP) segment amidst challenging global macroeconomic conditions.  **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:1]** **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:0]** 
- Looking ahead to 2026, Westlake anticipates **$200 million** in cost savings and an additional **$100 million** benefit from footprint optimization actions, such as the Pernis Shutdown, aimed at improving profitability.  **[1262823_0001262823-25-000061_ex991_20250930earningsrele.htm:1]**

Westlake Corporation Reports Q3 2025 Results with Significant Impairment Charge

- Westlake Corporation reported **net sales of $2.838 billion** for the third quarter of 2025, a decrease from **$3.117 billion** in the third quarter of 2024.  **[1262823_53b376db880740e39b3e89e0ed9442cf_0]** **[1262823_53b376db880740e39b3e89e0ed9442cf_8]** 
- The company recorded a **net loss of $782 million**, or **$6.06 per diluted common share**, for Q3 2025, primarily driven by a **non-cash impairment charge of $727 million** related to the North American Chlorovinyls business and **$17 million** in accrued expenses for asset shutdowns.  **[1262823_53b376db880740e39b3e89e0ed9442cf_0]** **[1262823_53b376db880740e39b3e89e0ed9442cf_1]** **[1262823_53b376db880740e39b3e89e0ed9442cf_3]** 
- Excluding these Identified Items, the net loss for the third quarter of 2025 was **$38 million**, or **$0.29 per share**, with EBITDA (excluding Identified Items) at **$313 million**.  **[1262823_53b376db880740e39b3e89e0ed9442cf_1]** 
- This EBITDA (excluding Identified Items) of **$313 million** for Q3 2025 was lower than the **$580 million** reported in Q3 2024, primarily due to lower average sales prices, reduced margins, and decreased sales volume in the Performance and Essential Materials segment, as well as lower average sales prices and period-related expenses in the Housing and Infrastructure Products segment.  **[1262823_53b376db880740e39b3e89e0ed9442cf_1]** 
- As of September 30, 2025, Westlake held **$2.1 billion** in cash, cash equivalents, and fixed-income investments, with total debt amounting to **$4.7 billion**.  **[1262823_53b376db880740e39b3e89e0ed9442cf_3]**

Westlake Corporation Reports Third Quarter 2025 Results

- Westlake reported **Net Sales of $2.8 billion** and a **Net Loss attributable to Westlake Corporation of $782 million**, resulting in **($6.06) Diluted EPS** for Q3 2025.  **[0001262823_2214949:0]** **[0001262823_2214949:6]** 
- The Q3 2025 results were significantly impacted by a **non-cash goodwill impairment charge of $727 million**, primarily affecting the Performance and Essential Materials (PEM) segment.  **[0001262823_2214949:1]** **[0001262823_2214949:6]** 
- The Housing and Infrastructure Products (HIP) segment recorded **EBITDA of $215 million**  **[0001262823_2214949:1]** , but its **2025 revenue and EBITDA margin are now expected at the low end** of previous guidance due to slower residential construction activity.  **[0001262823_2214949:2]** 
- The Performance and Essential Materials (PEM) segment's **EBITDA improved 73% QoQ to $90 million**  **[0001262823_2214949:1]** **[0001262823_2214949:4]** , benefiting from a **$36 million tailwind from better plant reliability**.  **[0001262823_2214949:4]** 
- Westlake achieved **~$115 million in company-wide cost savings year-to-date**, including **$40 million in Q3 2025**, towards its FY 2025 target of $150 million – $175 million, and is progressing towards **$200 million in identified cost savings for 2026**.  **[0001262823_2214949:1]** **[0001262823_2214949:0]**

Westlake Reports Q3 2025 Financial Results with Significant Goodwill Impairment

- Westlake Chemical Partners LP reported **net income attributable to the Partnership** of **$14.7 million**, or **$0.42 per limited partner unit**, for the third quarter of 2025.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]**  This was below the $18.1 million reported in Q3 2024 but in line with $14.6 million in Q2 2025.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]** 
- **Cash flows from operating activities** for Q3 2025 were **$105.2 million**, a decrease of $20.9 million from Q3 2024 but an increase of $96.1 million from Q2 2025.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]** 
- **MLP distributable cash flow** for Q3 2025 was **$14.9 million**, a decrease of $3.0 million compared to Q3 2024, primarily due to higher maintenance capital expenditures.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]** 
- The Partnership declared a quarterly distribution of **$0.4714 per unit** for Q3 2025, marking its 45th consecutive quarterly distribution.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]** **[1262823_9de0477a2dd946658dfde82724db2c1a_1]**  The trailing twelve-month coverage ratio for Q3 2025 was **0.75x**, down from 0.79x in Q2 2025.  **[1262823_9de0477a2dd946658dfde82724db2c1a_1]** 
- OpCo renewed its **Ethylene Sales Agreement** with Westlake through **2027** at existing terms, which provides a predictable, fee-based cash flow structure for 95% of OpCo's production.  **[1262823_9de0477a2dd946658dfde82724db2c1a_0]**

Westlake Chemical Partners LP Announces Third Quarter 2025 Results

- Westlake Chemical Partners announced the **renewal of the Ethylene Sales Agreement** between Westlake Chemical OpCo LP and Westlake Corporation.  **[1262823_55ca41a6987344279dcb05502c794b0a_0]** 
- The renewed agreement extends through **December 31, 2027**, with an initial term until **December 31, 2026**, and includes automatic 12-month renewal periods.  **[1262823_55ca41a6987344279dcb05502c794b0a_0]** 
- It maintains the **same pricing formula** and **sales volume protections**, facilitating continued offtake for **95% of the ethylene produced by OpCo**.  **[1262823_55ca41a6987344279dcb05502c794b0a_0]**  This has supported **45 consecutive quarterly distributions** to unitholders without decreases since the initial public offering in 2014.  **[1262823_55ca41a6987344279dcb05502c794b0a_0]** 
- Amendments were also made to the Services and Secondment Agreement and the Omnibus Agreement to align their terms with the Ethylene Sales Agreement and address indemnification.  **[1262823_55ca41a6987344279dcb05502c794b0a_0]**

Westlake Chemical Partners Announces Renewal of Ethylene Sales Agreement

- Westlake Corporation (WLK) has announced an agreement to acquire the global compounding solutions businesses of the **ACI/Perplastic Group** ("ACI").  **[1262823_0001262823-25-000056_ex991august262025.htm:0]** **[1262823_0001262823-25-000056_wlk-20250826.htm:1]** 
- ACI is a Portugal-based global manufacturer of specialty materials for the wire and cable sectors, reporting **net sales of approximately EUR 210 million** for the twelve months ended December 31, 2024.  **[1262823_0001262823-25-000056_ex991august262025.htm:0]** 
- This acquisition is expected to **expand Westlake's Housing & Infrastructure Products (HIP) business** and integrate new specialty products and technology into its portfolio.  **[1262823_0001262823-25-000056_ex991august262025.htm:0]** 
- The transaction is anticipated to close in **early 2026**, subject to customary closing conditions and regulatory approvals.  **[1262823_0001262823-25-000056_ex991august262025.htm:0]**

Westlake Corporation Announces Acquisition of ACI Compounding Solutions Business

WESTLAKE (WLK)